

3rd February 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UDTel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

East Sussex Healthcare NHS Trust does not differentiate between BLBCL and DLBCL. However, we have provided the number of admissions with a diagnosis of both conditions, discharged between July to December 2025, in the table below:

Number of Patients	Primary Diagnosis	Secondary Diagnosis
41	33	8

a. Of these patients, how many commenced treatment at your trust within the last 6 months?

15.

2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, 7
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 0
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 0
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) 7
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 0
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) 0
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) 1
- (DA)-EPOCH +/- R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) 0
- R-GemOX (rituximab, gemcitabine and oxaliplatin) 0

• Axicabtagene ciloleucel	0
• Tisagenlecleucel	0
• Epcoritamab	0
• Loncastuximab tesirine	0
• Glofitamab	0
• Any other SACT	0
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0

3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

• Axicabtagene ciloleucel (Yescarta)	0
• Tisagenlecleucel	0
• Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	0
• R-GemOX (rituximab, gemcitabine and oxaliplatin)	0
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0
• Glofitamab	0
• Any other treatments	0

4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?

0.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
 Wycliffe House
 Water Lane
 Wilmslow
 Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net